Advertisement

The Impact of Alternative Alkalinizing Agents on 24-Hour Urine Parameters

      Abstract

      Objectives

      To determine if alternative alkalinizing agents lead to similar changes in 24-hour urine pH and citrate compared to potassium citrate (KCIT). Many stone formers cannot tolerate KCIT due to side effects or cost. In these patients, we have prescribed potassium bicarbonate or sodium bicarbonate as alternative alkali (AA), though their efficacy is unclear.

      Methods

      We performed a retrospective cohort study of adult stone formers seen from 2000 to 2018 with 24-hour urine analyses. Two analyses were performed. The first evaluated the alkalinizing and citraturic effects in patients with baseline low urine pH or hypocitraturia off of any alkalinizing medications, who were subsequently treated with either KCIT or AA. The second analysis compared the pH and citrate in patients changing from KCIT to an AA. Reasons for switching were abstracted by chart review and cost savings percentages were calculated using GoodRx medication prices.

      Results

      When starting alkali therapy, the median increase in pH from baseline was 0.64 for KCIT and 0.51 for AA (P = .077), and the median increase in citrate from baseline was 231 mg for KCIT and 171 mg for AA (P = .109). When switching alkali therapy, median pH and citrate did not significantly change. Hyperkalemia (24%), GI upset (19%), and cost (17%) were the most common reasons cited for switching to an AA. AA represented a savings of 86%-92% compared to KCIT.

      Conclusion

      Alternative alkali appear to offer comparable improvements in 24-hour urine parameters and significant cost-savings compared to KCIT.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Scales Jr., CD
        • Smith AC
        • Hanley JM
        • et al.
        Prevalence of kidney stones in the United States.
        Eur Urol. 2012; 62: 160-165
        • Pearle MS
        • Calhoun EA
        • Curhan GC
        • et al.
        Urologic diseases in America project: urolithiasis.
        J Urol. 2005; 173: 848-857
        • Hyams ES
        • Matlaga BR
        Economic impact of urinary stones.
        Transl Androl Urol. 2014; 3: 278-283
        • Pearle MS
        • Goldfarb DS
        • Assimos DG
        • et al.
        Medical management of kidney stones: AUA guideline.
        J Urol. 2014; 192: 316-324
        • Turk C
        • Petrik A
        • Sarica K
        • et al.
        EAU guidelines on diagnosis and conservative management of urolithiasis.
        Eur Urol. 2016; 69: 468-474
        • Lotan Y
        Economics and cost of care of stone disease.
        Adv Chronic Kidney Dis. 2009; 16: 5-10
        • Zuckerman JM
        • Assimos DG
        Hypocitraturia: pathophysiology and medical management.
        Rev Urol. 2009; 11: 134-144
        • Barcelo P
        • Wuhl O
        • Servitge E
        • et al.
        Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis.
        J Urol. 1993; 150: 1761-1764
        • Pak CY
        • Fuller C
        • Sakhaee K
        • et al.
        Long-term treatment of calcium nephrolithiasis with potassium citrate.
        J Urol. 1985; 134: 11-19
        • Khatchadourian J
        • Preminger GM
        • Whitson PA
        • et al.
        Clinical and biochemical presentation of gouty diathesis - comparison of uric-acid versus pure calcium stone formation.
        J Urol. 1995; 154: 1665-1669
        • Phillips R
        • Hanchanale VS
        • Myatt A
        • et al.
        Citrate salts for preventing and treating calcium containing kidney stones in adults.
        Cochrane Database Syst Rev. 2015; CD010057
        • Pak CY
        • Sakhaee K
        • Fuller C
        Successful management of uric acid nephrolithiasis with potassium citrate.
        Kidney Int. 1986; 30: 422-428
        • Robinson MR
        • Leitao VA
        • Haleblian GE
        • et al.
        Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation.
        J Urol. 2009; 181: 1145-1150
        • Doizi S
        • Poindexter JR
        • Pearle MS
        • et al.
        Impact of potassium citrate vs citric acid on urinary stone risk in calcium phosphate stone formers.
        J Urol. 2018; 200: 1278-1284
        • Song Y
        • Hernandez N
        • Shoag J
        • Goldfarb DS
        • Eisner BH
        Potassium citrate decreases urine calcium excretion in patients with hypocitraturic calcium oxalate nephrolithiasis.
        Urolithiasis. 2016; 44: 145-148
        • Mattle D
        • Hess B
        Preventive treatment of nephrolithiasis with alkali citrate–a critical review.
        Urol Res. 2005; 33: 73-79
        • Pinheiro VB
        • Baxmann AC
        • Tiselius HG
        • et al.
        The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers.
        Urology. 2013; 82: 33-37
        • Fjellstedt E
        • Denneberg T
        • Jeppsson JO
        • et al.
        A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria.
        Urol Res. 2001; 29: 295-302
        • Lemann Jr., J
        • Gray RW
        • Pleuss JA
        Potassium bicarbonate, but not sodium bicarbonate, reduces urinary calcium excretion and improves calcium balance in healthy men.
        Kidney Int. 1989; 35: 688-695